Novation Applauds New FDA Guidance Documents on Biosimilars

Novation expressed its approval of the FDA draft guidance on biosimilars in a news release.

The company said the less expensive drugs could decrease costs by 20-30 percent when using European market as a model. However, Steven Lucio, director of pharmacy clinical solutions for Novation, said implementation of biosimilars will be a complicated process. Novation plans to expand two of its resources, the Drug Monograph Service and the biannual Drug Price Forecast, to include the availability of biosimilars.

Related Articles on the Supply Chain:
Developing and Launching a Long-Sleeved Scrub: Q&A With Myrna Chang of CA's O'Connor Hospital and Jennifer Walrich of Medline
Counterfeit Version of Cancer Drug Avastin Found in U.S.
GHX to Create Industry's First Implantable Devices Supply Chain Solution for Physician Preference Items

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers